Oramed Pharmaceuticals Inc

Financials

Cash from operating activities 12.44 M21.18 M27.92 M10.29 M8.41 M 10.59 M Cash from investing activities 4.63 M23.76 M30.21 M73.04 M105.82 M 22.55 M Cash from financing activities 23.79 M102.89 M10.78 M51.98 M52.04 M 1.93 M Free cash flow 12.36 M20.81 M27.42 M10.04 M8.39 M 10.57 M

Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.

ORMP

Financials

Oramed Pharmaceuticals Inc

新闻

Oramed将口服药物递送平台转移至Lifeward

Lifeward将以4700万美元收购Oramed口服蛋白质递送技术

Oramed股价上涨，收到Scilex 1800万美元付款

Oramed stock rises after receiving $18 million payment from Scilex

Oramed收到Scilex 1800万美元付款，宣布派发股息

Oramed receives $18 million payment from Scilex, declares dividend

Oramed Pharmaceuticals董事Leonard Sank将在任职18年后辞职

Oramed Pharmaceuticals director Leonard Sank to resign after 18 years

Oramed制药公司完成Scilex 2850万美元权证回购

Oramed Pharmaceuticals completes $28.5 million warrant repurchase by Scilex

Scilex Holding Co sells shares worth $12.7 million

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback